These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 37269857)

  • 1. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network.
    Ludwig H; Terpos E; van de Donk N; Mateos MV; Moreau P; Dimopoulos MA; Delforge M; Rodriguez-Otero P; San-Miguel J; Yong K; Gay F; Einsele H; Mina R; Caers J; Driessen C; Musto P; Zweegman S; Engelhardt M; Cook G; Weisel K; Broijl A; Beksac M; Bila J; Schjesvold F; Cavo M; Hajek R; Touzeau C; Boccadoro M; Sonneveld P
    Lancet Oncol; 2023 Jun; 24(6):e255-e269. PubMed ID: 37269857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma.
    Caimi PF; Pacheco Sanchez G; Sharma A; Otegbeye F; Ahmed N; Rojas P; Patel S; Kleinsorge Block S; Schiavone J; Zamborsky K; Boughan K; Hillian A; Reese-Koc J; Maschan M; Dropulic B; Sekaly RP; de Lima M
    Front Immunol; 2021; 12():745320. PubMed ID: 34712233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma.
    Mohan M; Chakraborty R; Bal S; Nellore A; Baljevic M; D'Souza A; Pappas PG; Berdeja JG; Callander N; Costa LJ
    Br J Haematol; 2023 Dec; 203(5):736-746. PubMed ID: 37287117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Siltuximab as a primary treatment for cytokine release syndrome in a patient receiving a bispecific antibody in a clinical trial setting.
    Lipe BC; Renaud T
    J Oncol Pharm Pract; 2023 Jun; 29(4):1006-1010. PubMed ID: 36464766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T cell redirecting bispecific antibodies for multiple myeloma: emerging therapeutic strategies in a changing treatment landscape.
    Kazandjian D; Kowalski A; Landgren O
    Leuk Lymphoma; 2022 Dec; 63(13):3032-3043. PubMed ID: 36059239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How I treat refractory CRS and ICANS after CAR T-cell therapy.
    Jain MD; Smith M; Shah NN
    Blood; 2023 May; 141(20):2430-2442. PubMed ID: 36989488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies.
    Freyer CW; Porter DL
    J Allergy Clin Immunol; 2020 Nov; 146(5):940-948. PubMed ID: 32771558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxicity Profile of Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapies in Multiple Myeloma: Pathogenesis, Prevention and Management.
    Markouli M; Ullah F; Unlu S; Omar N; Lopetegui-Lia N; Duco M; Anwer F; Raza S; Dima D
    Curr Oncol; 2023 Jul; 30(7):6330-6352. PubMed ID: 37504327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS).
    Wehrli M; Gallagher K; Chen YB; Leick MB; McAfee SL; El-Jawahri AR; DeFilipp Z; Horick N; O'Donnell P; Spitzer T; Dey B; Cook D; Trailor M; Lindell K; Maus MV; Frigault MJ
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 34996813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recognizing, defining, and managing CAR-T hematologic toxicities.
    Rejeski K; Subklewe M; Locke FL
    Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):198-208. PubMed ID: 38066881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome.
    Kotch C; Barrett D; Teachey DT
    Expert Rev Clin Immunol; 2019 Aug; 15(8):813-822. PubMed ID: 31219357
    [No Abstract]   [Full Text] [Related]  

  • 12. Novel treatment strategies for hematological malignancies in the immunotherapy era.
    Imai Y
    Int J Hematol; 2024 Jul; 120(1):3-5. PubMed ID: 38861242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed/refractory multiple myeloma.
    Martin TG; Mateos MV; Nooka A; Banerjee A; Kobos R; Pei L; Qi M; Verona R; Doyle M; Smit J; Sun W; Trancucci D; Uhlar C; van de Donk NWCJ; Rodriguez C
    Cancer; 2023 Jul; 129(13):2035-2046. PubMed ID: 36991547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Managing side effects: guidance for use of immunotherapies in multiple myeloma.
    Liang EC; Sidana S
    Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):348-356. PubMed ID: 38066898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T-cell exhaustion in multiple myeloma.
    Żyłka K; Kubicki T; Gil L; Dytfeld D
    Expert Rev Hematol; 2024 Jul; 17(7):295-312. PubMed ID: 38919090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CAR-T cell: Toxicities issues: Mechanisms and clinical management.
    Wallet F; Sesques P; Devic P; Levrard M; Ader F; Friggeri A; Bachy E
    Bull Cancer; 2021 Oct; 108(10S):S117-S127. PubMed ID: 34920794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early Use of Corticosteroids following CAR T-Cell Therapy Correlates with Reduced Risk of High-Grade CRS without Negative Impact on Neurotoxicity or Treatment Outcome.
    Lakomy T; Akhoundova D; Nilius H; Kronig MN; Novak U; Daskalakis M; Bacher U; Pabst T
    Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review.
    Géraud A; Hueso T; Laparra A; Bige N; Ouali K; Cauquil C; Stoclin A; Danlos FX; Hollebecque A; Ribrag V; Gazzah A; Goldschmidt V; Baldini C; Suzzoni S; Bahleda R; Besse B; Barlesi F; Lambotte O; Massard C; Marabelle A; Castilla-Llorente C; Champiat S; Michot JM
    Eur J Cancer; 2024 Jul; 205():114075. PubMed ID: 38733717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New forms of immunotherapy in uro-oncology : HLA-independent therapeutic approaches with bispecific antibodies and CAR T cells].
    Krebs M; Chatterjee M; Kübler H; Kalogirou C
    Urologie; 2023 Jul; 62(7):685-690. PubMed ID: 37341719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myeloma.
    Tacchetti P; Talarico M; Barbato S; Pantani L; Mancuso K; Rizzello I; Zamagni E; Cavo M
    Expert Rev Anticancer Ther; 2024 Jun; 24(6):379-395. PubMed ID: 38798125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.